Our Pricing

Wegovy Clinical Trial Results: Evidence-Based Weight Loss Data

Wegovy clinical trial results from the landmark STEP programme demonstrate significant weight loss outcomes for adults with obesity. Across multiple phase 3 trials involving over 4,500 participants, semaglutide 2.4mg (Wegovy) consistently delivered average weight reductions of 12-15% from baseline body weight over 68 weeks[1]. These robust clinical findings have positioned Wegovy as one of the most evidence-backed weight management treatments licensed by the MHRA for UK patients.

STEP Trial Programme: Wegovy Clinical Trial Results Overview

The Wegovy clinical trial results stem primarily from the STEP (Semaglutide Treatment Effect in People with obesity) programme, a comprehensive series of randomised, double-blind, placebo-controlled trials conducted across multiple countries including UK sites[1]. The STEP 1 trial, published in The New England Journal of Medicine, enrolled 1,961 adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities. Participants receiving once-weekly semaglutide 2.4mg achieved a mean weight loss of 14.9% at 68 weeks, compared to 2.4% in the placebo group[1].

Subsequent trials in the STEP series examined specific populations and treatment scenarios. STEP 2 focused on adults with type 2 diabetes, demonstrating 9.6% average weight reduction with Wegovy versus 3.4% with placebo[2]. STEP 3 combined semaglutide with intensive behavioural therapy, yielding 16.0% mean weight loss[2]. STEP 4 evaluated weight maintenance after initial treatment, showing participants who continued Wegovy maintained their weight loss whilst those switched to placebo regained 6.9% of body weight[3]. These wegovy clinical trial results collectively provide robust evidence across diverse patient populations and treatment durations.

Wegovy Clinical Trial Results: Key Efficacy Endpoints and Outcomes

The primary efficacy measure across wegovy clinical trial results was percentage change in body weight from baseline to week 68. In STEP 1, 86.4% of participants on semaglutide achieved ≥5% weight loss (versus 31.5% on placebo), whilst 69.1% achieved ≥10% weight loss (versus 12.0% on placebo)[1]. Notably, 50.5% of Wegovy-treated participants reached ≥15% weight reduction, a threshold associated with significant metabolic health improvements. These proportions far exceeded those observed with earlier weight management medications licensed in the UK.

Secondary endpoints in the wegovy clinical trial results included changes in waist circumference, systolic blood pressure, and lipid profiles. Participants treated with semaglutide 2.4mg experienced mean waist circumference reductions of 13.5 cm compared to 4.1 cm with placebo[1]. Systolic blood pressure decreased by an average of 6.2 mmHg in the Wegovy group. HbA1c levels in participants with prediabetes at baseline showed greater reductions with active treatment, and 84.1% of these individuals reverted to normoglycaemia compared to 47.8% on placebo[2]. These cardiometabolic benefits complement the weight loss outcomes observed across trials.

Patient-Reported Outcomes in Wegovy Trials

Beyond objective measures, wegovy clinical trial results incorporated patient-reported outcome tools to assess quality of life and physical functioning. The STEP 1 trial utilised the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) questionnaire, demonstrating significantly greater improvements in physical function, public distress, and total score domains for semaglutide-treated participants versus placebo[1]. These findings suggest that the weight loss achieved with Wegovy translates into meaningful improvements in daily functioning and wellbeing as experienced by patients themselves.

Safety Profile: Adverse Events in Wegovy Clinical Trial Results

The wegovy clinical trial results provide comprehensive safety data from long-term exposure to semaglutide 2.4mg. Gastrointestinal adverse events were the most frequently reported, occurring in 74% of Wegovy participants versus 47% of placebo recipients in STEP 1[1]. The most common specific events included nausea (44%), diarrhoea (32%), vomiting (25%), and constipation (24%), typically mild to moderate in severity and transient, peaking during dose escalation phases. Serious adverse events occurred in 9.8% of semaglutide participants versus 6.4% of placebo, though most were not treatment-related[1].

Discontinuation rates due to adverse events in wegovy clinical trial results ranged from 4.5% to 7.0% across STEP trials for semaglutide arms, compared to 2.4% to 3.2% for placebo[1][2]. Gallbladder-related events (cholelithiasis, cholecystitis) occurred in approximately 2.6% of Wegovy-treated participants versus 1.2% on placebo, consistent with rapid weight loss effects seen with other treatments[3]. No increased risk of pancreatitis, major adverse cardiovascular events, or medullary thyroid carcinoma was observed during the trials, though semaglutide carries a boxed warning regarding thyroid C-cell tumours based on rodent studies. All prescription of Wegovy at Cured Pharmacy follows clinical assessment by UK-registered prescribers who evaluate individual risk factors and contraindications.

Long-Term Wegovy Clinical Trial Results: STEP 5 Extended Duration Study

The STEP 5 trial extended the observation period to 104 weeks, providing crucial long-term wegovy clinical trial results for sustained weight management[4]. This randomised trial enrolled 304 adults with obesity who received once-weekly semaglutide 2.4mg or placebo for two years. At week 104, participants on Wegovy achieved a mean weight loss of 15.2% from baseline, compared to 2.6% with placebo—demonstrating that weight reduction not only persists but continues to accrue beyond the first year of treatment[4].

These extended wegovy clinical trial results address a critical question in obesity medicine: whether pharmacotherapy can deliver durable weight loss. The STEP 5 findings showed that 77.1% of semaglutide participants achieved ≥10% weight loss at two years, and 40.0% reached ≥20% reduction[4]. Importantly, the safety profile remained consistent with shorter-duration trials, with no new adverse signals emerging during prolonged exposure. For UK patients seeking evidence-based weight management through Cured Pharmacy, these long-term data provide reassurance that Wegovy's benefits can be maintained with continued treatment under appropriate medical supervision.

Weight Regain After Wegovy Discontinuation

The STEP 4 trial specifically examined what happens when Wegovy is stopped after initial weight loss. Participants who discontinued semaglutide and switched to placebo regained approximately two-thirds of their lost weight over the subsequent 48 weeks[3]. These wegovy clinical trial results underscore that obesity is a chronic condition requiring ongoing management, and that semaglutide works through active pharmacological mechanisms rather than simply initiating behavioural changes that persist independently. UK prescribers at Cured Pharmacy discuss long-term treatment strategies during clinical assessments to set realistic expectations for sustained weight management.

Wegovy Clinical Trial Results in Specific UK-Relevant Populations

Several STEP trials generated wegovy clinical trial results particularly relevant to UK patient demographics. STEP 2 enrolled adults with type 2 diabetes and BMI ≥27 kg/m², a population representing approximately 90% of UK adults with diabetes who are overweight or obese according to NHS data[2]. In this trial, semaglutide 2.4mg produced 9.6% mean weight loss and greater HbA1c reductions (-1.6%) compared to placebo (-0.4%), addressing both weight and glycaemic control simultaneously[2].

The STEP 8 trial compared semaglutide 2.4mg directly against liraglutide 3.0mg (Saxenda), another GLP-1 receptor agonist licensed for weight management in the UK[5]. This head-to-head wegovy clinical trial results showed semaglutide delivered superior weight loss: 15.8% versus 6.4% at 68 weeks. Twice as many participants on Wegovy achieved ≥15% weight reduction (70% versus 25%)[5]. For UK patients comparing treatment options at Cured Pharmacy, these comparative data inform evidence-based decision-making alongside cost considerations—Wegovy is available from £69.00 with once-weekly dosing versus daily injections required for liraglutide.

Accessing Wegovy Based on Clinical Trial Results: UK Availability at Cured Pharmacy

The compelling wegovy clinical trial results led to MHRA licensing in 2021 and subsequent NICE approval for NHS prescription under specific criteria (BMI ≥35 kg/m² or ≥32.5 kg/m² for certain ethnic groups, plus weight-related comorbidity)[6]. However, NHS supply constraints mean many eligible UK patients face extended waiting times. Cured Pharmacy offers private access to genuine UK-licensed Wegovy from £69.00, with transparent upfront pricing and free online consultation completed in under three minutes by UK-registered prescribers.

Every prescription at Cured Pharmacy follows the same clinical assessment protocols that guided participant selection in the wegovy clinical trial results. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team evaluate medical history, contraindications, and suitability based on MHRA-approved criteria. Treatment includes the same dose-escalation schedule used in STEP trials to minimise gastrointestinal side effects, starting at 0.25mg weekly and increasing to the maintenance dose of 2.4mg over 16-20 weeks. Patients receive ongoing support and can access prescriber advice throughout their treatment journey, mirroring the structured protocols that produced the robust efficacy outcomes seen in clinical trials.

Combining Wegovy with Lifestyle Interventions

All wegovy clinical trial results included lifestyle intervention components—participants received counselling on reduced-calorie diets (500 kcal/day deficit) and increased physical activity (150 minutes/week)[1][2]. STEP 3 intensified this behavioural support and achieved 16.0% mean weight loss, the highest in the programme[2]. These findings emphasise that Wegovy works synergistically with diet and exercise rather than replacing them. UK patients starting treatment through Cured Pharmacy receive guidance on evidence-based lifestyle modifications to optimise outcomes, reflecting the multimodal approach that underpinned the clinical trial successes.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 15 August 2026]
3. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
4. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
5. Rubino, D. M., Greenway, F. L., Khalid, U., O'Neil, P. M., Rosenstock, J., Sørrig, R., et al. (2022). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA, 327(2), 138-150. [accessed 15 August 2026]
6. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. [accessed 15 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.